aspp2 primary antibodies  (Bethyl)

Journal: Experimental and Therapeutic Medicine

Article Title: ASPP2 expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization

doi: 10.3892/etm.2021.9828

Figure Lengend Snippet: Baseline characteristics of the unresectable HCC patients with high or low expression of ASPP2 (n=232).

Article Snippet: The paraffin block was cut into 5-µm sections and then incubated with primary antibody for rat anti-human ASPP2 (BD Pharmingen) in 5% rabbit serum overnight at 4̊C followed by washing and incubation with ABC (avidin-linked biotin complex) rabbit anti-rat Ig.

Techniques: Expressing

Journal: Experimental and Therapeutic Medicine

Article Title: ASPP2 expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization

doi: 10.3892/etm.2021.9828

Figure Lengend Snippet: Baseline characteristics of the resectable HCC patients with high or low expression of ASPP2 (n=205).

Article Snippet: The paraffin block was cut into 5-µm sections and then incubated with primary antibody for rat anti-human ASPP2 (BD Pharmingen) in 5% rabbit serum overnight at 4̊C followed by washing and incubation with ABC (avidin-linked biotin complex) rabbit anti-rat Ig.

Techniques: Expressing

Journal: Experimental and Therapeutic Medicine

Article Title: ASPP2 expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization

doi: 10.3892/etm.2021.9828

Figure Lengend Snippet: Expression of Beclin-1 and ASPP2 in tissues from HCC patients with or without administration of TACE. Expression of ASPP2 in HCC tissue from patients with (A) sequential TACE followed by resection or (B) direct resection. (C) The ratio of expression of ASPP2 in the para-carcinoma to carcinoma tissues in the patients with sequential TACE followed by resection or direct resection. n=13, * P<0.05. Expression of Beclin-1 in the HCC tissue from patients with (D) sequential TACE followed by resection or (E) direct resection. (F) Negative correlation between the expression of Beclin-1 and ASPP2 in carcinoma tissue of patients with sequential TACE followed by resection (n=36). Student's t-test and linear correlation analysis were used for statistical analysis. P<0.05 indicates statistical difference. ASPP2, apoptosis-stimulating p53 protein 2; TACE, transcatheter arterial chemoembolization; HCC, hepatocellular carcinoma.

Article Snippet: The paraffin block was cut into 5-µm sections and then incubated with primary antibody for rat anti-human ASPP2 (BD Pharmingen) in 5% rabbit serum overnight at 4̊C followed by washing and incubation with ABC (avidin-linked biotin complex) rabbit anti-rat Ig.

Techniques: Expressing

Journal: Experimental and Therapeutic Medicine

Article Title: ASPP2 expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization

doi: 10.3892/etm.2021.9828

Figure Lengend Snippet: Multiple logistics regression analysis for the independent risk factor of 1-year mortality rate.

Article Snippet: The paraffin block was cut into 5-µm sections and then incubated with primary antibody for rat anti-human ASPP2 (BD Pharmingen) in 5% rabbit serum overnight at 4̊C followed by washing and incubation with ABC (avidin-linked biotin complex) rabbit anti-rat Ig.

Techniques: Expressing

Journal: Experimental and Therapeutic Medicine

Article Title: ASPP2 expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization

doi: 10.3892/etm.2021.9828

Figure Lengend Snippet: Survival analysis and expression of ASPP2 in the HCC patients after TACE. (A) The 1-year progression-free survival in unresectable HCC patients at initiation after neoadjuvant TACE combination and resection in all subjects with high expression (dotted line) and low expression of ASPP2 (solid line). (B) The 1-year overall survival in unresectable HCC patients at initiation following neoadjuvant TACE combination and resection in all subjects with high expression (dotted line) and low expression of ASPP2 (solid line). (C) The 1-year progression-free survival in resectable HCC patients following neoadjuvant TACE combination and resection in three groups subjects, including patients who were administered TACE with high expression (red dotted line) and low expression (black dotted line) of ASPP2 or who did not received neoadjunct TACE (black solid line). (D) The 1-year over survival in resectable HCC patients following neoadjuvant TACE combination and resection in three groups subjects, including patients who were administered TACE with high expression and low expression of ASPP2 or not. Survival analysis was used for the statistical analysis. The survival curve is depicted according to the Kaplan-Meier method. Red dotted line, patients administered TACE and with a high expression of ASPP2; Black dotted line, patients administered TACE and with a low expression of ASPP2; Black solid line, patients without TACE administration. ASPP2, apoptosis-stimulating p53 protein 2; TACE, transcatheter arterial chemoembolization; HCC, hepatocellular carcinoma.

Article Snippet: The paraffin block was cut into 5-µm sections and then incubated with primary antibody for rat anti-human ASPP2 (BD Pharmingen) in 5% rabbit serum overnight at 4̊C followed by washing and incubation with ABC (avidin-linked biotin complex) rabbit anti-rat Ig.

Techniques: Expressing